Genzyme Ireland’s 483 Is Not a Manufacturing Story. It’s a Sponsor Oversight Indictment.
FDA's June 2026 warning letter to Genzyme Ireland over Altuviiio manufacturing exposes how post-approval CGMP oversight collapses at the...
Sobi’s Gout CRL Is a Third-Party Manufacturing Indictment — And the Industry Wrote the Script
FDA issued Sobi a CRL for NASP on June 26, 2026, citing third-party manufacturing failures. Here's the operational breakdown...
Zoll Medical’s FDA Warning Letter Reveals the QC Failure Sponsors Keep Funding
FDA's April 2026 warning letter to Zoll Medical exposes quality control and MDR violations at a cardiopulmonary device maker...
Jazz and PharmaMar Just Ran Out of Runway: Zepzelca’s Confirmatory Failure Is an Accelerated Approval System Under Stress
Zepzelca's Phase 3 LAGOON trial missed overall survival in SCLC—Jazz's second confirmatory failure, six years after a 105-patient single-arm...
Zynlonta’s 3-to-1 Death Ratio Is the Accelerated Approval System Grading Its Own Homework
ADC Therapeutics' LOTIS-5 trial shows 13.2% fatal events vs. 4.6% in controls—a 3:1 death imbalance that exposes accelerated approval's...
Eli Lilly’s Five-Day Ultimatum: How Pharma Is Weaponizing 340B Deadlines to Squeeze Hospital Trial Networks
Eli Lilly gave 1,000+ hospitals five days to submit claims data or lose 340B discounts—exposing how pharma giants shift...
The FDA Said No. Europe Said Yes. Someone Is Wrong About Camizestrant.
AstraZeneca's Etcamah won EMA approval weeks after FDA adcom rejection—exposing a regulatory split that demands answers on endpoint standards...
Aardvark’s Clinical Hold Isn’t Bad Luck — It’s a Pre-Clinical Characterization Failure
FDA placed a full clinical hold on Aardvark's ARD-101 after a cardiac event in a healthy volunteer. Here's what...
BeOne Medicines Got Caught Running a Blood Cancer Ad That Outran Its Own Data
FDA flagged BeOne's Brukinsa TV ad 'Clarity' for misleading visuals—BeOne's third OPDP enforcement letter in under 18 months. Here's...
The FY2024 BIMO Report Confirms It: Sponsor Oversight Failures Are Now Structural
FDA's FY2024 Bioresearch Monitoring report shows 25% of sponsor inspections drew a Form 483, with the same recurring findings...